Sign in Subscribe
Genetic research

Research Reveals Higher Risk of Metastasis in Non-Small Cell Lung Cancer Patients with HER2 Exon 20 Mutations

Strategic Insights

— 1 min read

Researchers at Maoming People's Hospital conducted a study to investigate the clinical and genetic characteristics of HER2 exon 20 oncogenic variants in non-small cell lung cancer (NSCLC) patients. The study analyzed 51 NSCLC patients with HER2 mutations, identifying 20 (39.3%) with exon 20 mutations. These patients showed a higher rate of metastasis to the lungs, lymph nodes, and brain, and had a higher risk of drug resistance, leading to worse outcomes compared to non-exon 20 mutations.

Key Takeaways:

  • The study analyzed 51 NSCLC patients with HER2 mutations, including 20 with exon 20 mutations.
  • Patients with exon 20 mutations had a higher rate of metastasis to the lungs, lymph nodes, and brain compared to non-exon 20 mutations.
  • Exon 20 mutations were more prevalent in the non-baseline group (55.0% vs. 29.0%, P = 0.049) and males (75.0%, P = 0.025).
  • The median age of the HER2-altered subgroup was 58.5 years, and adenocarcinoma was the most prevalent subtype (96.1%).
  • The study highlights the urgent need for targeted therapies aimed at exon 20 insertions to improve survival and treatment outcomes in this subgroup.
  • The research was funded by the Science And Technology Fund of Maoming City, Guangdong Province Science And Technology Innovation Strategy Special Fund in Maoming City, Special Science And Technology Fund of Maoming City, High-level Hospital Construction Research Project of Maoming People's Hospital, Double Talent Plan of Maoming People's Hospital, and Natural Science Foundation of Guangdong Province.

Statistics:

  • 7.83% of NSCLC patients (51 out of 651) harbored HER2 alterations, including 20 (3.08%) with exon 20 mutations.
  • 68.6% of patients with metastatic sites had lung metastasis.
  • 52.9% of patients with metastatic sites had lymph node metastasis.
  • 43.1% of patients with metastatic sites had brain metastasis.
  • The median age of the HER2-altered subgroup was 58.5 years.

Sources:

  • Genomic and clinical characterization of HER2 exon 20 mutations in non-small cell lung cancer: insights from a multicenter study in South China (BMC Cancer, 2025, 25(1):1-10, BMC Cancer - http://bmccancer.biomedcentral.com)
  • NewsRx (Research on Non-Small Cell Lung Cancer Described by Researchers at Maoming People's Hospital (Genomic and clinical characterization of HER2 exon 20 mutations in non-small cell lung cancer: insights from a multicenter study in South China)). Health & Medicine Week. May 16, 2025; p 5653.

Read more